SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?

SOPHiA GENETICS SA SOPH shares rallied 7% in the last trading session to close at $8.53. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.7% loss over the past four weeks.

SOPHiA GENETICS scored a strong price increase on investors’ optimism surrounding the company’s solid second quarter of 2026 performance. The company posted strong revenue growth of 27% year-over-year, while also improving adjusted EBITDA loss by 27%. Additionally, the company raised 2026 revenue guidance to a range of $94 million to $96 million (previously $92 million to $94 million), representing 22% to 24% year-over-year growth.

This company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of +56.7%. Revenues are expected to be $23.89 million, up 22.8% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For SOPHiA GENETICS, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SOPH going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

SOPHiA GENETICS is part of the Zacks Medical Info Systems industry. Schrodinger, Inc. SDGR, another stock in the same industry, closed the last trading session 26.4% higher at $30.24. SDGR has returned 20.6% in the past month.

For Schrodinger, the consensus EPS estimate for the upcoming report has changed +4.1% over the past month to -$0.66. This represents a change of -46.7% from what the company reported a year ago. Schrodinger currently has a Zacks Rank of #3 (Hold).

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research